{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T19:57:10Z","timestamp":1788465430153,"version":"build-2803163510"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,9,1]]},"DOI":"10.1093\/ndt\/gfl293","type":"journal-article","created":{"date-parts":[[2006,6,9]],"date-time":"2006-06-09T20:28:45Z","timestamp":1149884925000},"page":"2507-2512","source":"Crossref","is-referenced-by-count":173,"title":["Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis\u2014a randomized study"],"prefix":"10.1093","volume":"21","author":[{"given":"Akihiko","family":"Takahashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Takase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Toriyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Sugiura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Kurita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuzo","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuaki","family":"Dohi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2006,6,9]]},"reference":[{"key":"key\n\t\t\t\t20171011060313_BIB1","doi-asserted-by":"crossref","unstructured":"El Nahas AM, Bello AK. Chronic kidney disease: the global challenge. Lancet2005; 365: 331\u2013340","DOI":"10.1016\/S0140-6736(05)17789-7"},{"key":"key\n\t\t\t\t20171011060313_BIB2","unstructured":"Dzau VJ. Mechanism of protective effects of ACE inhibition on coronary artery disease. Eur Heart J1998; 19 [Suppl J]: J2\u2013J6"},{"key":"key\n\t\t\t\t20171011060313_BIB3","doi-asserted-by":"crossref","unstructured":"Ross R. Atherosclerosis\u2014an inflammatory disease. N Engl J Med1999; 340: 115\u2013126","DOI":"10.1056\/NEJM199901143400207"},{"key":"key\n\t\t\t\t20171011060313_BIB4","doi-asserted-by":"crossref","unstructured":"Ruiz-Ortega M, Lorenzo O, Ruperez M, Egido J. ACE inhibitors and AT1 receptor antagonists \u2013 beyond the haemodynamic effect. Nephrol Dial Transplant2000; 15: 561\u2013565","DOI":"10.1093\/ndt\/15.5.561"},{"key":"key\n\t\t\t\t20171011060313_BIB5","doi-asserted-by":"crossref","unstructured":"Brasier AR, Recinos AR, Eledrisi MS. Vascular inflammation and the renin\u2013angiotensin system. Arterioscler Thromb Vasc Biol2002; 22: 1257\u20131266","DOI":"10.1161\/01.ATV.0000021412.56621.A2"},{"key":"key\n\t\t\t\t20171011060313_BIB6","doi-asserted-by":"crossref","unstructured":"Dohi Y, Ohashi M, Sugiyama M, Takase H, Sato K, Ueda R. Candesartan reduces oxidative stress and inflammation in patients with essential hypertension. Hypertens Res2003; 26: 691\u2013697","DOI":"10.1291\/hypres.26.691"},{"key":"key\n\t\t\t\t20171011060313_BIB7","doi-asserted-by":"crossref","unstructured":"Dahlof B, Devereux RB, Kjeldsen SE et al. for the LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol. Lancet2002; 359: 995\u20131003","DOI":"10.1016\/S0140-6736(02)08089-3"},{"key":"key\n\t\t\t\t20171011060313_BIB8","doi-asserted-by":"crossref","unstructured":"Collins AJ. Cardiovascular mortality in end-stage renal disease. Am J Med Sci2003; 325: 163\u2013167","DOI":"10.1097\/00000441-200304000-00002"},{"key":"key\n\t\t\t\t20171011060313_BIB9","doi-asserted-by":"crossref","unstructured":"Pfeffer MA, Swedberg K, Granger CB et al. for the CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall Programme. Lancet2003; 362: 759\u2013766","DOI":"10.1016\/S0140-6736(03)14282-1"},{"key":"key\n\t\t\t\t20171011060313_BIB10","doi-asserted-by":"crossref","unstructured":"Granger CB, McMurray JJ, Yusuf S et al. for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative Trial. Lancet2003; 362: 772\u2013776","DOI":"10.1016\/S0140-6736(03)14284-5"},{"key":"key\n\t\t\t\t20171011060313_BIB11","doi-asserted-by":"crossref","unstructured":"Cohn JN, Tognoni G. for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med2001; 345: 1667\u20131675","DOI":"10.1056\/NEJMoa010713"},{"key":"key\n\t\t\t\t20171011060313_BIB12","doi-asserted-by":"crossref","unstructured":"Efrati S, Zaidenstein R, Dishy V et al. ACE inhibitors and survival of hemodialysis patients. Am J Kidney Dis2002; 40: 1023\u20131029","DOI":"10.1053\/ajkd.2002.36340"},{"key":"key\n\t\t\t\t20171011060313_BIB13","doi-asserted-by":"crossref","unstructured":"Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation1977; 55: 613\u2013618","DOI":"10.1161\/01.CIR.55.4.613"},{"key":"key\n\t\t\t\t20171011060313_BIB14","doi-asserted-by":"crossref","unstructured":"Yasue H, Yoshimura M, Sumida H et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation1994; 90: 195\u2013203","DOI":"10.1161\/01.CIR.90.1.195"},{"key":"key\n\t\t\t\t20171011060313_BIB15","doi-asserted-by":"crossref","unstructured":"Goto T, Takase H, Toriyama T et al. Increased circulating levels of natriuretic peptides predict future cardiac event in patients with chronic hemodialysis. Nephron2002; 92: 610\u2013615","DOI":"10.1159\/000064100"},{"key":"key\n\t\t\t\t20171011060313_BIB16","doi-asserted-by":"crossref","unstructured":"Grieve DJ, Shah AM. Oxidative stress in heart failure. More than just damage. Eur Heart J2003; 24: 2161\u20132163","DOI":"10.1016\/j.ehj.2003.10.015"},{"key":"key\n\t\t\t\t20171011060313_BIB17","doi-asserted-by":"crossref","unstructured":"Kameda K, Matsunaga T, Abe N et al. Correlation of oxidative stress with activity of matrix metalloproteinase in patients with coronary artery disease. Possible role for left ventricular remodelling. Eur Heart J2003; 24: 2180\u20132185","DOI":"10.1016\/j.ehj.2003.09.022"},{"key":"key\n\t\t\t\t20171011060313_BIB18","doi-asserted-by":"crossref","unstructured":"Cannella G, Paoletti E, Delfino R, Peloso G, Rolla D, Molinari S. Prolonged therapy with ACE inhibitors induces a regression of left ventricular hypertrophy of dialyzed uremic patients independently from hypotensive effects. Am J Kidney Dis1997; 30: 659\u2013664","DOI":"10.1016\/S0272-6386(97)90490-X"},{"key":"key\n\t\t\t\t20171011060313_BIB19","unstructured":"Paoletti E, Cannella G. Arterial hypertension and left ventricular hypertrophy in hemodialysis patients. Clin Nephrol2002; 58 [Suppl 1]: S46\u2013S51"},{"key":"key\n\t\t\t\t20171011060313_BIB20","doi-asserted-by":"crossref","unstructured":"Yasunari K, Maeda K, Watanabe T, Nakamura M, Yoshikawa J, Asada A. Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy. J Am Coll Cardiol2004; 43: 2116\u20132123","DOI":"10.1016\/j.jacc.2003.12.051"},{"key":"key\n\t\t\t\t20171011060313_BIB21","doi-asserted-by":"crossref","unstructured":"Lindholm LH, Dahlof B, Edelman JM et al. LIFE study group. Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study. Lancet2003; 362: 619\u2013620","DOI":"10.1016\/S0140-6736(03)14183-9"},{"key":"key\n\t\t\t\t20171011060313_BIB22","doi-asserted-by":"crossref","unstructured":"Solomon SD, Wang D, Finn P et al. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation2004; 110: 2180\u20132183","DOI":"10.1161\/01.CIR.0000144474.65922.AA"},{"key":"key\n\t\t\t\t20171011060313_BIB23","doi-asserted-by":"crossref","unstructured":"Verma S, Strauss M. Angiotensin receptor blockers and myocardial infarction. Br Med J2004; 329: 1248\u20131249","DOI":"10.1136\/bmj.329.7477.1248"},{"key":"key\n\t\t\t\t20171011060313_BIB24","doi-asserted-by":"crossref","unstructured":"Julius S, Kjeldsen SE, Weber M et al. VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine; the VALUE randomised trial. Lancet2004; 363: 2022\u20132031","DOI":"10.1016\/S0140-6736(04)16451-9"},{"key":"key\n\t\t\t\t20171011060313_BIB25","doi-asserted-by":"crossref","unstructured":"Demers C, McMurray JJ, Swedberg K et al. CHARM Investigators. Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure. JAMA2005; 294: 1794\u20131798","DOI":"10.1001\/jama.294.14.1794"},{"key":"key\n\t\t\t\t20171011060313_BIB26","doi-asserted-by":"crossref","unstructured":"Kalantar-Zadeh K, Ikizler TA, Block G, Avram MM, Kopple JD. Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences. Am J Kidney Dis2003; 42: 864\u2013881","DOI":"10.1016\/j.ajkd.2003.07.016"},{"key":"key\n\t\t\t\t20171011060313_BIB27","doi-asserted-by":"crossref","unstructured":"Raggi P. Effects of excess calcium load on the cardiovascular system measured with electron beam tomography in end-stage renal disease. Nephrol Dial Transplant2002; 17: 332\u2013335","DOI":"10.1093\/ndt\/17.2.332"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/21\/9\/2507\/7624932\/gfl293.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,19]],"date-time":"2019-04-19T04:47:09Z","timestamp":1555649229000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/ndt\/article\/21\/9\/2507\/1939380\/Candesartan-an-angiotensin-II-type1-receptor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6,9]]},"references-count":27,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2006,6,9]]},"published-print":{"date-parts":[[2006,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfl293","relation":{},"ISSN":["1460-2385","0931-0509"],"issn-type":[{"value":"1460-2385","type":"electronic"},{"value":"0931-0509","type":"print"}],"subject":[],"published-other":{"date-parts":[[2006,9]]},"published":{"date-parts":[[2006,6,9]]}}}